by admin | Dec 14, 2015 | All News, Industry News
The following document was approved by the Medical and Scientific Advisory Council (MASAC) on August 15, 2015, and adopted by the NHF Board of Directors on October 6, 2015. Inhibitors are an important public health issue that result in increased morbidity and...
by admin | Dec 8, 2015 | All News, Industry News
December 8, 2015 The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand...
by admin | Nov 17, 2015 | All News, Industry News
November 17, 2015 The US Food and Drug Administration (FDA) recently approved Baxalta’s ADYNOVATE, a new longer- lasting recombinant factor VIII (rFVII) product. The new therapy is indicated for the on-demand treatment of bleeding episodes, and for routine...
by admin | Oct 22, 2015 | All News, Industry News
The nation’s largest independent specialty pharmacy has been named to a specially trained distribution network to dispense COAGADEX® for the treatment of hereditary factor X deficiency. FLINT, Mich.—Diplomat Pharmacy, Inc. (NYSE: DPLO) announced that it has secured...
by admin | Oct 10, 2014 | All News, Industry News
The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first...
by admin | Sep 29, 2014 | All News, Industry News
Grifols has announced the availability of a new 2,000 IU/vial assay size for ALPHANATE®, the company’s plasma-derived factor VIII (FVIII)/von Willebrand factor product. The new vial size is available starting October 1, 2014. ALPHANATE is indicated for the prevention...
